Response versus remission in obsessive-compulsive disorder

Journal of Clinical Psychiatry

Volumn 67, Issue 2, 2006, Pages 269-276

  Simpson, Helen Blair ^a,b   Huppert, Jonathan D ^c   Petkova, Eva ^a,b   Foa, Edna B ^c   Liebowitz, Michael R ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; POST HOC ANALYSIS; PRIORITY JOURNAL; REMISSION; SYMPTOMATOLOGY; TREATMENT RESPONSE;

EID: 33644830659     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0214     Document Type: Article

References (37)

1. Simpson HB, Fallon BA. Obsessive-compulsive disorder: an overview. J Psychiatr Pract 2000;6:3-17
2. Bystritsky A, Saxena S, Maidment K, et al. Quality-of-life changes among patients with obsessive-compulsive disorder in a partial hospitalization program. Psychiatr Serv 1999;50:412-414
3. Koran LM. Quality of life in obsessive-compulsive disorder. Psychiatr Clin North Am 2000;23:509-517
4. Frank E, Prien RF, Jarret RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-855
5. Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005;162:151-161
6. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
7. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
8. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 2: validity. Arch Gen Psychiatry 1989;46:1012-1016
9. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991;59:12-19
10. Simpson HB, Liebowitz MR, Foa EB, et al. Post-treatment effects of exposure therapy versus clomipramine in OCD. Depress Anxiety 2004;19:225-233
11. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
12. Kozak MJ, Foa EB. Mastery of Obsessive-Compulsive Disorder: A Cognitive-Behavioral Approach. San Antonio, Tex: The Psychological Corporation; 1997
13. Goodman WK, Kozak MJ, Liebowitz M, et al. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1996;11:21-29
14. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-295
15. Hollander E, for the Paroxetine OCD Study Group, Allen A, Steiner M, et al. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 2003;64:1113-1121
16. Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001;16: 75-86
17. Cottraux J, Note I, Yao SN, et al. A randomized controlled trial of cognitive therapy versus intensive behavior therapy in obsessive compulsive disorder. Psychother Psychosom 2001;70:288-297
18. Tollefson GD, Rampey AH Jr, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-567
19. Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. Arch Gen Psychiatry 1991;48:730-738
20. Hohagen F, Winkelmann G, Rasche-Raeuchle H, et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo: results of a multicentre study. Br J Psychiatry 1998;173:71-78
21. van Oppen P, de Haan E, van Balkom AJ, et al. Cognitive therapy and exposure in vivo in the treatment of obsessive compulsive disorder. Behav Res Ther 1995;33:379-390
22. McLean PD, Whittal ML, Thordarson DS, et al. Cognitive versus behavior therapy in the group treatment of obsessive-compulsive disorder. J Consult Clin Psychol 2001;69:205-214
23. Woody SR, Steketee G, Chambless DL. Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale. Behav Res Ther 1995;33:597-605
24. Hollander E, Zohar J. Introduction. Beyond refractory obsessions and anxiety states: toward remission. J Clin Psychiatry 2004;65(suppl 14):3-5
25. Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002;5:181-191
26. Eddy KT, Dutra L, Bradley R, et al. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 2004;24:1011-1030
27. Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry 2001;62(suppl 12):5-9
28. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
29. Leon AC, Shear MK, Portera L, et al. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 1992;27:78-82
30. Eisen JL, Goodman WK, Keller MB, et al. Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study. J Clin Psychiatry 1999;60:346-351
31. Bergeron R, Ravindran AV, Chaput Y, et al. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study. J Clin Psychopharmacol 2002;22:148-154
32. Simpson H, Franklin M, Cheng J, et al. Standard criteria for relapse are needed in Obsessive Compulsive Disorder. Depress Anxiety 2005;21:1-8
33. Abramowitz JS. Variants of exposure and response prevention in the treatment of obsessive-compulsive disorder: a meta-analysis. Behav Ther 1996;27:583-600
34. Abramowitz JS, Foa EB, Franklin ME. Exposure and ritual prevention for obsessive-compulsive disorder: effects of intensive versus twice-weekly sessions. J Consult Clin Psychol 2003;71:394-398
35. Ackerman D, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 2002;22:309-317
36. Kobak KA, Greist JH, Jefferson JW, et al. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology (Berl) 1998;136:205-216
37. Koran LM, Leventhal JL, Fireman B, et al. Pharmacotherapy of obsessive-compulsive disorder in a health maintenance organization. Am J Health Syst Pharm 2000;57:1972-1978